Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.

OBJECTIVE The main genetic risk factor for rheumatoid arthritis (RA), the HLA region, has been known for 25 years. Previous research has demonstrated, within the RA population, an association between HLA-DRB1 alleles carrying the shared epitope (SE) and antibodies directed against cyclic citrullinated peptides (anti-CCP antibodies). We undertook this study to make the first comparison of SE allele frequencies in the healthy population with those in RA patients who do or do not harbor anti-CCP antibodies. METHODS HLA-DRB1 typing was performed in 408 RA patients from the Leiden Early Arthritis Clinic (the Leiden EAC; a Dutch population-based inception cohort in which disease course was followed up over time), in 423 healthy Dutch controls, and in 720 affected members of 341 US multiplex (sibpair) families of Caucasian origin from the North American RA Consortium (NARAC) with well-established disease and fulfilling the American College of Rheumatology classification criteria for RA. The presence of anti-CCP antibodies was determined by enzyme-linked immunosorbent assay. RESULTS For the Leiden EAC, the odds ratio (OR) describing the association of 2 copies of the SE allele with anti-CCP positivity (using no copies of the SE allele in the healthy control group as the referent) was 11.79 (P < 0.0001), while the OR for 1 SE allele was 4.37 (P < 0.0001). No association with the SE was observed in the Dutch anti-CCP-negative RA patients. For the NARAC families, linkage and association analysis revealed the SE to be associated only with anti-CCP-positive disease and not with anti-CCP-negative disease. Stratified analyses indicated that anti-CCP antibodies primarily mediated association of the SE with joint damage or disease persistence. CONCLUSION HLA-DRB1 alleles encoding the SE are specific for disease characterized by antibodies to citrullinated peptides, indicating that these alleles do not associate with RA as such, but rather with a particular phenotype.

[1]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[2]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[3]  A S Rigby,et al.  Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. , 2000, Arthritis and rheumatism.

[4]  F. Arnett Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[5]  A. Sette,et al.  Cutting Edge: The Conversion of Arginine to Citrulline Allows for a High-Affinity Peptide Interaction with the Rheumatoid Arthritis-Associated HLA-DRB1*0401 MHC Class II Molecule1 , 2003, The Journal of Immunology.

[6]  M. V. van Leeuwen,et al.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[7]  G Strandberg,et al.  Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) , 2004, Annals of the rheumatic diseases.

[8]  H. Schumacher,et al.  Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset , 2000, Arthritis research.

[9]  H. Visser,et al.  A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[10]  F. Breedveld,et al.  Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. , 2004, Arthritis and rheumatism.

[11]  Xiangli Xiao,et al.  Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. , 2003, Arthritis and rheumatism.

[12]  C. Allaart,et al.  The Leiden Early Arthritis Clinic. , 2003, Clinical and experimental rheumatology.

[13]  Madhukar Pai,et al.  Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. , 2004, Arthritis and rheumatism.

[14]  F. Breedveld,et al.  Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[15]  M. Rewers,et al.  Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[16]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[17]  J. Hazes,et al.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. , 2000, Arthritis and rheumatism.

[18]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[19]  P. Shekelle,et al.  How to read radiographs according to the Sharp/van der Heijde method. , 1999 .

[20]  G. Abecasis,et al.  Merlin—rapid analysis of dense genetic maps using sparse gene flow trees , 2002, Nature Genetics.